2025-08-12T11:31:01-05:00 2024-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2024-01-01 263727917 Reagan-Udall Foundation for the Food and Drug Administration Inc REAG 2028492075 1333 New Hampshire Ave NW 420 Washington DC 20036 Susan C Winckler Chief Executive Officer 2028492075 2025-08-12 1 1 Jie Chen CPA P01049760 7038930300 2024 2025-03-06 01:10:19Z Susan C Winckler 1333 New Hampshire Ave NW 420 Washington DC 20036 8631216 0 X www.reaganudall.org X 2009 MD Advance the mission of the Food and Drug Administration to modernize product development, accelerate innovation, and enhance product safety. 17 17 24 20 0 0 4698615 4788188 3399686 3407304 145939 167709 -27513 -121627 8216727 8241574 10000 0 0 0 2651989 3351164 0 0 140488 5128287 4528975 7790276 7880139 426451 361435 6385158 7237733 2209540 2700113 4175618 4537620 Advance the mission of the Food and Drug Administration to modernize product development, accelerate innovation, and enhance product safety. 0 0 3828811 3098372 Advancing Regulatory Science- Provide data assets, evaluation tools, and career development opportunities to help FDA assess the risks and benefits of regulated products. Examples include the the Innovation in Medical Evidence and Development Surveillance (IMEDS) Program, Fellowship in Regulatory Science & Innovation, and the ASH Real-World Evidence Consortium. 2115839 13500 Supporting Development and Dissemination of Reliable Information- Improve public understanding of the risks and benefits of FDA-regulated products. Identify priority areas for consumer, patient, and provider education in areas of emerging science. Examples include Expanded Access Navigator, Nutrition Communications Network, Improving Human Health Risk Communication, and Animal Health and Veterinary Industry Analysis. 1540472 295432 Facilitating Engagement and Information Exchange - Facilitate multi-stakeholder collaboration to accelerate evidence generation and dissemination. Enable expert analysis, candid discussion, and actionable recommendations relevant to the FDA Mission. Examples include Healthy Rule Roundtables, Food Traceability Roundtables, Primary Mitochondrial Diseases Workshop, FDA Patient Listening Sessions, and Biosimilars Development Regulatory Science Accelerator. 7485122 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 31 0 1 24 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X Dave Woodbury 2028492067 1333 New Hampshire Ave NW 420 Washington DC 20036 Richard L Schilsky Board Chair 4.00 X X 0 0 0 Adrian F Hernandez Board Vice Chair 4.00 X X 0 0 0 Debra L Ness Treasurer 4.00 X X 0 0 0 Lynne Zydowsky Secretary 4.00 X X 0 0 0 Edward J Allera Director 4.00 X 0 0 0 Christie Boutte Director 4.00 X 0 0 0 Phil Febbo Director 4.00 X 0 0 0 David C Fajgenbaum Director 4.00 X 0 0 0 William N Hait Director 4.00 X 0 0 0 James EK Hildreth Director 4.00 X 0 0 0 Esther Krofah Director 4.00 X 0 0 0 Phuong Khanh PK Morrow Director 4.00 X 0 0 0 Richard Moscicki Director 4.00 X 0 0 0 Reed V Tuckson Director 4.00 X 0 0 0 Pietro Antonio Tataranni Director 4.00 X 0 0 0 Andrew C von Eschenbach Director 4.00 X 0 0 0 Sumbul Desai Director 4.00 X 0 0 0 Susan C Winckler RPh JD Chief Executive Officer 40.00 X 448815 0 38316 Amar Bhat PhD Chief Operating Officer 40.00 X 227004 0 34161 Carla Rodriguez-Watson PhD Director, Research 40.00 X 221228 0 25657 Lea Ann Browning-McNee MA Director, Communication and Stakeholder Engagement 40.00 X 185985 0 31595 David E Woodbury Jr MBA Director, Operations 40.00 X 172960 0 32298 Carolyn Hiller Senior Advisor for Innovation and Strategic Partne 40.00 X 164513 0 31660 Esther Boadi Engagement Manager 40.00 X 121425 0 16216 1541930 0 209903 7 0 1 0 Angie Hoth 905 Rider Street Iowa City IA 52246 Professional consulting services 125000 Calibre CPA Group PLLC 7501 Wisconsin Avenue Suite 1200 W Bethesda MD 20814 Accounting services 110716 Alston & Bird LLP PO Box 933124 Atlanta GA 311933124 Legal services 110000 3 401000 3697045 690143 4788188 IMEDS Contract 541900 3407304 3407304 3407304 166488 166488 250000 248779 1221 1221 1221 13236 401000 140863 -127627 -127627 Other 900099 6000 6000 6000 8241574 3407304 0 46082 X 748296 701652 22509 24135 2093790 1963278 62981 67531 120686 113163 3630 3893 193705 181631 5826 6248 194687 182551 5856 6280 110961 110599 167 195 133553 133553 3443267 3431563 5400 6304 23882 23804 36 42 31245 28792 705 1748 201336 195799 1669 3868 268186 251256 7793 9137 4542 4380 25 137 168331 162320 924 5087 37174 34255 839 2080 11295 10408 255 632 Professional Developmen 62788 58874 1889 2025 Dues and Subscriptions 19962 18394 451 1117 IRB Expense 7902 7876 12 14 Scientific Publishing 4430 4416 6 8 121 111 3 7 7880139 7485122 254529 140488 526766 523642 3310505 3532603 704030 711555 148785 1126950 46148 106196 456671 360942 117750 95729 250893 75016 5626 2925 1274655 1063117 6385158 7237733 403452 1361354 311414 84941 1494674 1253818 2209540 2700113 X 4121734 4452463 53884 85157 4175618 4537620 6385158 7237733 X 361435 5567 -5000 X X 0 1 X 1 1 1 X 2391995 2762920 5204924 4698615 4788188 19846642 2391995 2762920 5204924 4698615 4788188 19846642 19846642 22326 1358 30611 132034 166488 352817 1144 1090 50872 6000 59106 20258565 15632730 0.97970 0.98400 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 26254 9377 16877 205678 140638 65040 224739 210927 13812 95729 Deposits 26308 Right-of-use assets - operating lease 1036809 1063117 Lease liability - operating lease 1253818 1253818 X 8388004 5567 140863 146430 8241574 0 8241574 8026002 145863 145863 7880139 0 7880139 Part X, Line 2: Management has evaluated the Foundation's tax positions and concluded that the Foundation's financial statements do not include any uncertain tax positions. Part XI, Line 2d - Other Adjustments: Direct benefits to donors 140,863. Part XII, Line 2d - Other Adjustments: Direct benefits to donors 140,863. Write-off of contribution 5,000. 2024 Innovations in RS Awards 414236 401000 13236 80190 60673 414236 401000 13236 80190 60673 140863 -127627 X 0 0 0 0 0 0 0 0 0 Susan C Winckler RPh JD Chief Executive Officer 448815 0 0 0 0 0 20700 0 17616 0 487131 0 0 0 Amar Bhat PhD Chief Operating Officer 227004 0 0 0 0 0 13877 0 20284 0 261165 0 0 0 Carla Rodriguez-Watson PhD Director, Research 221228 0 0 0 0 0 13733 0 11924 0 246885 0 0 0 Lea Ann Browning-McNee MA Director, Communication and Stakehol 185985 0 0 0 0 0 11737 0 19858 0 217580 0 0 0 David E Woodbury Jr MBA Director, Operations 172960 0 0 0 0 0 10674 0 21624 0 205258 0 0 0 Carolyn Hiller Senior Advisor for Innovation and St 164513 0 0 0 0 0 9871 0 21789 0 196173 0 0 0 Form 990, Part VI, Section B, line 11b After the Form 990 is prepared by the independent accountants it is reviewed by the Chief Executive Officer and the Treasurer before being filed with the IRS. Form 990, Part VI, Section B, line 12c No director, officer, employee, fellow or trainee of the Foundation (hereinafter "Interested Persons") shall take any action on or participate in the consideration or determination of any Foundation matter in which he or she, his or her spouse, minor child, general partner, non-federal organization in which he or she is serving as an officer, director, trustee, general partner or employee, or any person or nonfederal organization with whom he or she is negotiating or has any arrangement concerning potential employment, has a financial interest. In addition to actual conflicts of interest, Interested Persons are also obliged to avoid actions that could be perceived or interpreted to be in conflict with the Foundation's best interests. Interested Persons shall disclose their financial interest in entities doing business with the Foundation and refrain from participating in decisions affecting transactions between the Foundation and those other entities without approval by the Board of Directors. Form 990, Part VI, Section B, line 15a The CEO's performance and compensation is annually reviewed and approved by the Executive Committee with input from the Board. This entire process is documented. Salaries of all staff are reviewed annually by the CEO using compensation survey data for comparable size and type organizations. Form 990, Part VI, Section C, line 19 The Foundation makes its governing documents, conflict of interest policy, and financial statements available to the public upon request. Form 990, Part IX, line 11g Temporary Staff Expense: Program service expenses 7,593. Management and general expenses 244. Fundraising expenses 261. Total expenses 8,098. Staff Recruiting Expense: Program service expenses 2,588. Management and general expenses 4. Fundraising expenses 4. Total expenses 2,596. Other Professional Fees: Program service expenses 54,563. Management and general expenses 83. Fundraising expenses 97. Total expenses 54,743. Program Consultants: Program service expenses 1,096,273. Management and general expenses 1,651. Fundraising expenses 1,934. Total expenses 1,099,858. Data Partners: Program service expenses 2,265,700. Management and general expenses 3,411. Fundraising expenses 3,999. Total expenses 2,273,110. Payroll Service Fees: Program service expenses 4,846. Management and general expenses 7. Fundraising expenses 9. Total expenses 4,862. Form 990, Part XI, line 9: Write-off of contribution -5,000. Form 990, Part XII, Line 2c: The Foundation's Finance Committee is responsible for oversight of the audit, including selection of the independent accountant. The process has not changed from prior years.